HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

60.250

-1.550-2.51%

Volume:184.63K

Turnover:11.05M

Market Cap:10.24B

PE:-28.69

High:61.500

Open:60.600

Low:58.300

Close:61.800

52wk High:95.800

52wk Low:43.600

Shares:170.00M

HK Float Shares:170.00M

Volume Ratio:0.45

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:-17.59%

ROA:-3.85%

PB:5.08

PE(LYR):-28.69

PS:18.90

Loading ...

Overview Company News Filings

RIBOLIFE-B (06938) 2026 Interim Results: Global Partnerships Fuel Revenue Surge While Core Pipelines and Platform Value Continue to Unlock

RIBOLIFE-B Swings to Profit on 304% Revenue Surge, Driven by Licensing Deals

Bulletin Express

Suzhou Ribo Life Science Swings to FY26 H1 Profit of RMB 23.45 Million; Revenue Rises to RMB 419.74 Million

Hong Kong Stock Market Movers | RIBOLIFE-B (06938) Surges Over 9% on Hang Seng Composite Index Inclusion, First-Half Revenue Expected to Rise Up to 3.2-Fold

Ribo Life Science Sets 27 Aug 2026 Board Meeting to Approve 1H26 Results and Consider Interim Dividend

Bulletin Express

Suzhou Ribo Life Science Board Meets to Review Interim Results, Consider Dividend

Suzhou Ribo Life Science Expects Revenue of Rmb311 Million-RMB436 Million for Six Months

Suzhou Ribo Life Science Co - Expected Hy Revenue Growth Mainly Driven by Madrigal Pharmaceuticals and Boehringer Ingelheim Collaborations

THOMSON REUTERS

Ribo Life Science Secures EMA Approval to Launch Phase 2b MRCT of siRNA Candidate Vortosiran for AF-Related Stroke Prevention

Bulletin Express

Suzhou Ribo Life Science Co - Ema Approves Initiation of Phase 2B Trial of Vortosiran for Spaf

THOMSON REUTERS

Suzhou Ribo Wins EMA Approval for Phase 2b Vortosiran Trial in Stroke Prevention for Atrial Fibrillation

RIBOLIFE-B Buys Back Shares for HK$4.22 Million

Suzhou Ribo Files HKEX Next-day Disclosure Return on Share Repurchase Cancellation

Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on Sirna-mediated Fxi Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease

THOMSON REUTERS

Suzhou Ribo Life Science Co - no Serious Adverse or Major Bleeding Events Observed in Vortosiran Phase 2a Trial

THOMSON REUTERS

Suzhou Ribo Reports Positive Phase 2a Results for Vortosiran

MT Newswires Live

RiboLife-B's Pioneering siRNA Drug Demonstrates Potent, Long-Lasting, and Safe Anticoagulation in New Data, Targeting a Multi-Billion Dollar Market

Positive Phase 2A Results for Vortosiran in Chronic Coronary Disease Announced

RIBOLIFE-B Spends HK$3.83 Million to Repurchase 79,000 H Shares, Treasury Stock Climbs to 0.49 Million

Bulletin Express

RIBOLIFE-B (06938) Executes HK$3.83 Million Share Buyback on July 17

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/06938/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":60.25,"timestamp":1788163726690,"preClose":61.8,"halted":0,"volume":184625,"delay":0,"changeRate":-0.02508090614886727,"floatShares":170000000,"shares":170000000,"eps":-2.100221,"marketStatus":"Not Yet Opened","change":-1.55,"latestTime":"08-31 16:08:46","open":60.6,"high":61.5,"low":58.3,"amount":11052216,"amplitude":0.05178,"askPrice":60.3,"askSize":200,"bidPrice":60.2,"bidSize":1400,"shortable":0,"etf":0,"ttmEps":-1.149,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788226200000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":61.8,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"volumeRatio":0.451422,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170000000,"roa":"-3.85%","roe":"-17.59%","lyrEps":-2.100221,"volumeRatio":0.451422,"shares":170000000,"dividePrice":0,"high":61.5,"amplitude":0.05178,"preClose":61.8,"low":58.3,"week52Low":43.6,"pbRate":"5.08","psRate":"18.90","week52High":95.8,"institutionHeld":0,"latestPrice":60.25,"committee":0.75,"eps":-2.100221,"divideRate":0,"volume":184625,"delay":0,"ttmEps":-1.149,"open":60.6,"prevYearClose":57.97,"prevWeekClose":61.8,"prevMonthClose":47.16,"prevQuarterClose":46.9,"fiveDayClose":61.4,"twentyDayClose":46.64,"sixtyDayClose":55.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"06938","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787794200000,"name":null,"time":"","dateTimestamp":1787760000000,"actualEps":null},{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1784476800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-08-28","current":-52.436902,"percent":0,"low":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"high":-23.913403,"avg":-32.410788,"sd":6.666018,"marketCap":10540293438},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-05","current":-28.193848,"twenty":-40.051892,"median":-35.061307,"eighty":-30.899503,"marketCap":9073521212},{"date":"2026-06-12","current":-27.046231,"twenty":-39.859077,"median":-34.61525,"eighty":-30.390832,"marketCap":8698300410},{"date":"2026-06-18","current":-26.187923,"twenty":-39.726813,"median":-33.720381,"eighty":-29.853022,"marketCap":8442468045},{"date":"2026-06-26","current":-23.913403,"twenty":-39.627323,"median":-32.945231,"eighty":-29.564677,"marketCap":7671559851},{"date":"2026-07-03","current":-27.120201,"twenty":-39.476172,"median":-32.527699,"eighty":-28.324896,"marketCap":8706828155},{"date":"2026-07-10","current":-25.658884,"twenty":-39.120404,"median":-32.474833,"eighty":-27.529192,"marketCap":8227568858},{"date":"2026-07-17","current":-25.917703,"twenty":-38.802803,"median":-32.09845,"eighty":-26.657872,"marketCap":8340135099},{"date":"2026-07-24","current":-28.402389,"twenty":-38.680546,"median":-32.07594,"eighty":-26.891702,"marketCap":9141743176},{"date":"2026-07-31","current":-24.94248,"twenty":-38.662044,"median":-31.566896,"eighty":-26.553964,"marketCap":8043369555},{"date":"2026-08-07","current":-27.580979,"twenty":-37.939269,"median":-30.913769,"eighty":-26.515913,"marketCap":8911494047},{"date":"2026-08-14","current":-27.888785,"twenty":-37.902214,"median":-30.842167,"eighty":-26.553964,"marketCap":9022354739},{"date":"2026-08-21","current":-28.090305,"twenty":-37.770699,"median":-30.35874,"eighty":-26.553964,"marketCap":9107632194},{"date":"2026-08-28","current":-53.27383,"twenty":-37.770699,"median":-30.842167,"eighty":-26.562391,"marketCap":10540293438}],"updateTime":1788202790207},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1170677910","title":"RIBOLIFE-B (06938) 2026 Interim Results: Global Partnerships Fuel Revenue Surge While Core Pipelines and Platform Value Continue to Unlock","url":"https://stock-news.laohu8.com/highlight/detail?id=1170677910","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170677910?lang=en_us&edition=fundamental","pubTime":"2026-08-28 08:48","pubTimestamp":1787878112,"startTime":"0","endTime":"0","summary":"On August 27, RIBOLIFE-B (06938) released its 2026 interim results. The recent explosive growth in the global oligonucleotide therapeutics market and the continuous breakthroughs in industry...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107996237","title":"RIBOLIFE-B Swings to Profit on 304% Revenue Surge, Driven by Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=1107996237","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107996237?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:43","pubTimestamp":1787831014,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B, 06938) reported a sharp turnaround for 1H 2026, underpinned by upfront and milestone payments from global partners Madrigal Pharmaceuticals and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"RIBOLIFE-B Swings to Profit on 304% Revenue Surge, Driven by Licensing Deals","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662090767","title":"Suzhou Ribo Life Science Swings to FY26 H1 Profit of RMB 23.45 Million; Revenue Rises to RMB 419.74 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662090767","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662090767?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:14","pubTimestamp":1787829268,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science swings to FY26 H1 profit of RMB 23.45 million; revenue rises to RMB 419.74 millionSuzhou Ribo Life Science posted revenue of RMB 419.7 million, up 304.3% year over year.Profit","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL69kLR8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102363568","title":"Hong Kong Stock Market Movers | RIBOLIFE-B (06938) Surges Over 9% on Hang Seng Composite Index Inclusion, First-Half Revenue Expected to Rise Up to 3.2-Fold","url":"https://stock-news.laohu8.com/highlight/detail?id=1102363568","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102363568?lang=en_us&edition=fundamental","pubTime":"2026-08-24 11:32","pubTimestamp":1787542351,"startTime":"0","endTime":"0","summary":"Shares of RIBOLIFE-B (06938) jumped more than 9% in early trading, last up 8.9% at HK$58.15 with turnover reaching HK$32.03 million.On the news front, Hang Seng Indexes Company announced its...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1161","BK4585","06938","KCAI","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140772281","title":"Ribo Life Science Sets 27 Aug 2026 Board Meeting to Approve 1H26 Results and Consider Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1140772281","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140772281?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:06","pubTimestamp":1786957617,"startTime":"0","endTime":"0","summary":"Ribo Life Science has scheduled a board meeting for Thursday, 27 August 2026. Directors will review and approve the unaudited results for the six months ended 30 June 2026, decide on the timing of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660870485","title":"Suzhou Ribo Life Science Board Meets to Review Interim Results, Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2660870485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660870485?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:45","pubTimestamp":1786956331,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science board meets to review interim results, consider dividendAug. 27, 2026: Suzhou Ribo Life Science board meeting to review interim results for the six months ended June 30, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL7pnh1S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655627148","title":"Suzhou Ribo Life Science Expects Revenue of Rmb311 Million-RMB436 Million for Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2655627148","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655627148?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:35","pubTimestamp":1785324940,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Ribo Life Science Expects Revenue Of RMB311 Million-RMB436 Million For Six MonthsJuly 29 (Reuters)-Suzhou Ribo Life Science Co Ltd6938.HK:EXPECTS REVENUE OF RMB311 MILLION-RMB436 MILLION ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V0W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655248866","title":"Suzhou Ribo Life Science Co - Expected Hy Revenue Growth Mainly Driven by Madrigal Pharmaceuticals and Boehringer Ingelheim Collaborations","url":"https://stock-news.laohu8.com/highlight/detail?id=2655248866","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655248866?lang=en_us&edition=fundamental","pubTime":"2026-07-29 18:18","pubTimestamp":1785320283,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V0W7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119391095","title":"Ribo Life Science Secures EMA Approval to Launch Phase 2b MRCT of siRNA Candidate Vortosiran for AF-Related Stroke Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=1119391095","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119391095?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:06","pubTimestamp":1785240379,"startTime":"0","endTime":"0","summary":"On 28 July 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) disclosed that the European Medicines Agency has authorised the initiation of ORBIT-XI-AF, a Phase 2b multi-regional clinical...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654900192","title":"Suzhou Ribo Life Science Co - Ema Approves Initiation of Phase 2B Trial of Vortosiran for Spaf","url":"https://stock-news.laohu8.com/highlight/detail?id=2654900192","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654900192?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:58","pubTimestamp":1785239934,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nFWN43U15S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001925","title":"Suzhou Ribo Wins EMA Approval for Phase 2b Vortosiran Trial in Stroke Prevention for Atrial Fibrillation","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001925","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654001925?lang=en_us&edition=fundamental","pubTime":"2026-07-28 19:58","pubTimestamp":1785239929,"startTime":"0","endTime":"0","summary":"Suzhou Ribo wins EMA approval for Phase 2b vortosiran trial in stroke prevention for atrial fibrillationSuzhou Ribo Life Science secured European Medicines Agency clearance to start a Phase 2b trial o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL1qmxLt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162346052","title":"RIBOLIFE-B Buys Back Shares for HK$4.22 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1162346052","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162346052?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:44","pubTimestamp":1784897051,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced a share buyback on July 24, 2026.The company spent approximately HK$4.2237 million to repurchase 78,400 shares.The repurchase price ranged from HK$52.6 to HK$54.4 per share.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653808262","title":"Suzhou Ribo Files HKEX Next-day Disclosure Return on Share Repurchase Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2653808262","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653808262?lang=en_us&edition=fundamental","pubTime":"2026-07-24 20:37","pubTimestamp":1784896639,"startTime":"0","endTime":"0","summary":"Suzhou Ribo files HKEX next-day disclosure return on share repurchase cancellationSuzhou Ribo repurchased 78,400 H shares on July 24 for treasury, no shares repurchased for cancellation.Buyback price ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL2ZBZxp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750982","title":"Ribo Discloses Positive Data from Vortosiran Phase 2a Trial - World's First Clinical Data on Sirna-mediated Fxi Inhibition Following Multiple Dosing in Patients with Coronary Artery Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653750982?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:23","pubTimestamp":1784723004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA5PZQHL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653075098","title":"Suzhou Ribo Life Science Co - no Serious Adverse or Major Bleeding Events Observed in Vortosiran Phase 2a Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653075098","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653075098?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:23","pubTimestamp":1784723004,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUA5PZQHL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653752817","title":"Suzhou Ribo Reports Positive Phase 2a Results for Vortosiran","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752817","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752817?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:09","pubTimestamp":1784718575,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science  reported positive Phase 2a results for its investigational therapy vortosiran  in patients with chronic coronary artery disease.The study showed the small interfering RNA therapy was generally well tolerated and achieved dose-dependent, long-lasting suppression of coagulation factor XI activity in patients receiving aspirin therapy, with no treatment-related serious adverse events or major bleeding reported, according to a Hong Kong bourse filing on Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146461811","title":"RiboLife-B's Pioneering siRNA Drug Demonstrates Potent, Long-Lasting, and Safe Anticoagulation in New Data, Targeting a Multi-Billion Dollar Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1146461811","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146461811?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:03","pubTimestamp":1784718212,"startTime":"0","endTime":"0","summary":"RiboLife-B (06938) has unveiled new Phase IIa data for its core candidate, Vortosiran (RBD4059), at the CPIC conference, reinforcing the drug's profile as a potent, durable, and safe therapy. The...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172610777","title":"Positive Phase 2A Results for Vortosiran in Chronic Coronary Disease Announced","url":"https://stock-news.laohu8.com/highlight/detail?id=1172610777","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172610777?lang=en_us&edition=fundamental","pubTime":"2026-07-22 16:38","pubTimestamp":1784709529,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (ASX: 06938) has announced the presentation of positive results from a European Phase 2a study evaluating vortosiran (RBD4059) in patients with chronic coronary artery disease (CAD). The...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152367346","title":"RIBOLIFE-B Spends HK$3.83 Million to Repurchase 79,000 H Shares, Treasury Stock Climbs to 0.49 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1152367346","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152367346?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:21","pubTimestamp":1784287280,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B; HKEX: 06938) disclosed a share buyback executed on 17 July 2026. The company repurchased 79,000 H shares on the Hong Kong Stock Exchange at prices...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113024488","title":"RIBOLIFE-B (06938) Executes HK$3.83 Million Share Buyback on July 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1113024488","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113024488?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:11","pubTimestamp":1784286714,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (ASX: 06938) has disclosed the execution of a share repurchase on July 17, 2026. The company repurchased 79,000 of its own shares, with the total expenditure for the transaction amounting to approximately HK$3.83 million.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":96,"code":"91000000","status":"200"}]}}